How to Treat Shingles

Shingles, or herpes zoster, is a painful, blistering skin rash caused by reactivation of the varicella-zoster virus—the same virus responsible for chickenpox. After primary infection, the virus lies dormant in dorsal root ganglia and can reactivate years later, typically presenting as a unilateral, dermatomal rash often accompanied by severe neuropathic pain.

Effective management hinges on early intervention. Antiviral medications—including acyclovir, valacyclovir, and famciclovir—are first-line treatments and should ideally be initiated within 72 hours of rash onset to reduce viral replication, accelerate lesion healing, and lower the risk of complications such as postherpetic neuralgia (PHN). Valacyclovir and famciclovir offer improved bioavailability and more convenient dosing regimens compared with acyclovir.

Pain control is integral to treatment. For acute pain, nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen may suffice for mild cases; however, moderate-to-severe pain often requires adjunctive therapy—such as gabapentin, pregabalin, or tricyclic antidepressants like nortriptyline—to target neuropathic mechanisms. In select cases, short-term corticosteroids (e.g., prednisone) may be considered alongside antivirals to mitigate inflammation, though evidence for long-term benefit remains limited and risks must be weighed carefully.

Supportive care includes keeping lesions clean and dry, avoiding scratching or rupturing blisters to prevent secondary bacterial infection, and using topical calamine lotion or cool compresses for symptomatic relief. Patients with ophthalmic involvement (zoster ophthalmicus), Ramsay Hunt syndrome, or disseminated disease require urgent specialist referral and often intravenous antiviral therapy.

Prevention plays a critical role: the recombinant zoster vaccine (RZV, Shingrix) is recommended for immunocompetent adults aged 50 years and older—and for immunocompromised individuals aged 19 years and older—to significantly reduce shingles incidence and PHN risk. Vaccination remains effective even in those with prior shingles episodes or previous receipt of the live attenuated zoster vaccine (Zostavax).